Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,469 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Astrocytoma Clear all
Completed Phase 1Phase 2 Interventional

Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain

NCT00039572
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
Interventions
boronophenylalanine-fructose complex
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 19, 2026, 2:01 AM EDT
Recruiting Phase 2 Interventional

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

NCT04623931
View directory record Official record
Conditions
Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, IDH-Wildtype, Glioblastoma, Oligoastrocytoma, Oligodendroglioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
Other · Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 19, 2026, 2:01 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas

NCT01338857
View directory record Official record
Conditions
neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
Interventions
Sorafenib (Nexavar)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 19, 2026, 2:01 AM EDT
Completed Phase 2 Interventional

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00305656
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
cediranib maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 19, 2026, 2:01 AM EDT
Not listed Phase 2 Interventional

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

NCT01903330
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar
Drug
Lead sponsor
Epitopoietic Research Corporation
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
3
States / cities
Orange, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 19, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Brain Tumors

NCT00003457
View directory record Official record
Conditions
Refractory Brain Tumors
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 19, 2026, 2:01 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

NCT03393000
View directory record Official record
Conditions
Glioblastoma
Interventions
Trans Sodium Crocetinate plus SOC, Standard of Care (SOC)
Drug · Other
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Irvine, California • Redwood City, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 19, 2026, 2:01 AM EDT
Completed Phase 2 Interventional

Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor

NCT00004068
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 19, 2026, 2:01 AM EDT
Completed Phase 1 Interventional

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

NCT00006368
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 19, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients

NCT00504660
View directory record Official record
Conditions
Anaplastic Glioma of Brain, Glioblastoma Multiforme, Brain Cancer
Interventions
Capecitabine, Celecoxib (Celebrex), Temozolomide, Lomustine, 6-Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 19, 2026, 2:01 AM EDT
Terminated Phase 2 Interventional Results available

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

NCT03973918
View directory record Official record
Conditions
High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
Interventions
Encorafenib, Binimetinib, Research Bloods, Tumor Tissue
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 19, 2026, 2:01 AM EDT
Completed Phase 1 Interventional

Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00053183
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
conventional surgery, brachytherapy, radiation therapy
Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 19, 2026, 2:01 AM EDT
Terminated Phase 1Phase 2 Interventional

Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00005856
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
oxaliplatin, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 19, 2026, 2:01 AM EDT
Completed Phase 1 Interventional

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

NCT04474353
View directory record Official record
Conditions
Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
Optune, Gadolinium, Temozolomide, Stereotactic radiosurgery (SRS)
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 19, 2026, 2:01 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

NCT05222802
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
ERAS-801
Drug
Lead sponsor
Katmai Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 19, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Everolimus in Treating Patients With Recurrent Low-Grade Glioma

NCT00823459
View directory record Official record
Conditions
Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Neoplasm
Interventions
Everolimus, Archival Tissue Analysis
Drug · Other
Lead sponsor
Susan Chang
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 19, 2026, 2:01 AM EDT
Completed Not applicable Interventional Results available

Mathematical Model-Adapted Radiation In Glioblastoma

NCT03557372
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Mathematical Model-Adapted Radiation Fractionation Schedule
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 19, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

NCT00667394
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions
Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 19, 2026, 2:01 AM EDT
Terminated Phase 1 Interventional

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT03422094
View directory record Official record
Conditions
Glioblastoma
Interventions
NeoVax, Nivolumab, Ipilimumab, Research blood draw, Leukapheresis for research
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 19, 2026, 2:01 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

NCT05039281
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
Atezolizumab, Cabozantinib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 19, 2026, 2:01 AM EDT
Terminated Phase 1 Interventional

SU5416 in Treating Children With Recurrent or Progressive Brain Tumors

NCT00006247
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
semaxanib
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Oct 19, 2026, 2:01 AM EDT
Terminated Early Phase 1 Interventional

Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6

NCT04074785
View directory record Official record
Conditions
GBM, Glioblastoma, Brain Tumor, Brain Tumor, Recurrent
Interventions
Abemaciclib, Bevacizumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 19, 2026, 2:01 AM EDT
Completed Phase 2 Interventional

Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

NCT04051606
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Regorafenib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 19, 2026, 2:01 AM EDT
Not yet recruiting Not applicable Interventional

Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being

NCT07628647
View directory record Official record
Conditions
Brain Cancer
Interventions
Group Self-Management Sessions, Educational Materials Only
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 19, 2026, 2:01 AM EDT